Atrial Fibrillation Before and After Patent Foramen Ovale Closure Study — ALFA ROMEO  

Atrial Fibrillation Clinical Trial

Official title: Atrial Fibrillation Before and After Patent Foramen Ovale Closure Study

Status Recruiting

Clinical Trial Summary

The aim of the ALFA ROMEO study is to better understand the association between cryptogenic stroke, PFO, PFO closure and AF.

Clinical Trial Description

For patients with cryptogenic stroke and PFO, a better understanding of the exact incidence of new-onset AF before and after PFO closure, its occurrence during follow-up, its persistence or reversibility and its prognostic impact is critical: If only a PFO, but no AF is available, then PFO closure followed by a limited duration of antiplatelet therapy is indicated. If on the other hand side a PFO and AF is found, lifelong therapeutic anticoagulation is mandatory.

By using the contemporary ICM protocols to search for silent AF in patients with cryptogenic stroke and a PFO for 3 months before PFO closure, ALFA ROMEO will help to understand the relationship of silent and previously undetected AF in the setting of PFO and investigate the true incidence of new-onset AF and its temporal course after effective PFO closure. Our findings will have the potential to impact on the future diagnostic and therapeutic management of patients with cryptogenic stroke and a PFO ;

Related Conditions & MeSH terms

• Atrial Fibrillation
• Cryptogenic Stroke
• Foramen Ovale, Patent
• Ischemic Stroke

• NCT number: NCT04881578
• Study type: Observational
• Source: University Hospital, Basel, Switzerland
• Contact: Raban Jeger, Prof Dr med
• Phone: +41 61 265 25 25
• Email: raban.jeger@usb.ch
• Status: Recruiting
• Start date: March 31, 2021
• Completion date: May 31, 2027